Previous Close | 92.96 |
Open | 92.56 |
Bid | 92.50 x 800 |
Ask | 92.63 x 1000 |
Day's Range | 91.83 - 93.89 |
52 Week Range | 61.58 - 178.71 |
Volume | |
Avg. Volume | 518,157 |
Market Cap | 5.167B |
Beta (5Y Monthly) | 0.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ASND
– Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 – Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label Extension Data in adult hypoparathyroidism on Monday, June 13 – PaTHway Trial results represent the second consecutive successful pivotal Phase 3 trial of a TransCon product candidate COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its pre
- VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone - These results demonstrate the ability of TransCon technology to deliver consistent and reproducible results for patients across a broad range of geographies and populations COPENHAGEN, Denmark, May 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology - Jesper Høiland, Global Chief Commercial Officer, will retire and become a senior advisor to Ascendis Pharma - Endocrinology commercial team will continue to focus on building U.S. market leadership for SKYTROFA® (lonapegsomatropin-tcgd) and preparing for other anticipated TransCon™